Results 211 to 220 of about 340,090 (253)

Pyrimidine containing RSV fusion inhibitors

Bioorganic & Medicinal Chemistry Letters, 2005
The knowledge of SAR in a series of biphenyl anionic RSV inhibitors has been broadened by synthesis and testing of analogs with pyrimidine linkers. Generally, pyrimidine compounds were much harder to synthesize, and their anti-RSV activity was lower in comparison with triazine analogs.
Antonia, Nikitenko, Yuri, Raifeld, Boris, Mitsner, Howard, Newman   +3 more
openaire   +2 more sources

Salicylamide inhibitors of influenza virus fusion

Bioorganic & Medicinal Chemistry Letters, 2000
Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural ...
K D, Combrink, H B, Gulgeze, K L, Yu, B C, Pearce, A K, Trehan, J, Wei, M, Deshpande, M, Krystal, A, Torri, G, Luo, C, Cianci, S, Danetz, L, Tiley, N A, Meanwell   +13 more
openaire   +2 more sources

Fusion/entry inhibitors as therapies for HIV

Expert Opinion on Emerging Drugs, 2001
A combination of three or more antiretroviral drugs, commonly termed 'highly active antiretroviral therapy' (HAART), has become the standard-of-care treatment for HIV-related disease in the developed world. Since its initiation in the mid 1990s, HAART has led to substantial reductions in both mortality and morbidity.
S, Redshaw, M, Westby
openaire   +2 more sources

Inhibition of HIV-1 by Fusion Inhibitors

Current Pharmaceutical Design, 2010
The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion.
Dirk, Eggink, Ben, Berkhout, Rogier W, Sanders   +2 more
openaire   +2 more sources

HIV entry and fusion inhibitors

Expert Opinion on Emerging Drugs, 2004
Human immunodeficiency virus (HIV) is a retrovirus that is the causative agent of acquired immunodeficiency syndrome (AIDS). Current HIV therapy is based on targeting two critical enzymes in the viral replication machinery: reverse transcriptase and a virally encoded protease. Although mortality rates due to HIV infection have been dramatically reduced,
openaire   +2 more sources

Inhibitors that target fusion

2007
The process of viral entry offers several advantages for drug intervention. Targeting extracellular events eliminates challenges in ensuring adequate drug delivery into cells. Disabling HIV before integration of viral DNA into host cells also prevents the potential for establishment of viral persistence in longlived cells.
Wang Wei, Carol D. Weiss
openaire   +1 more source

Inhibitors of HIV cellular fusion

Expert Opinion on Therapeutic Patents, 2000
HIV infection continues to be a major global health problem. Current anti-HIV therapies targeting reverse transcriptase and protease enzymes suffer from high cost, a high probability of engendering resistance and adverse side effects following prolonged use. Thus, we are faced with the need to develop new antiviral strategies with more potent compounds
Jim A Turpin, OM Zack Howard
openaire   +1 more source

Entry and fusion inhibitors of HIV

Expert Opinion on Therapeutic Patents, 2004
Considerable advances have been made towards finding compounds that are active as inhibitors of the entry and fusion of HIV. The discovery of chemokines a few years ago focused the attention on coreceptor inhibitors, in addition to fusion and attachment blockers.
S. Rusconi, E. Bulgheroni, P. Citterio
openaire   +1 more source

Is there a future for antiviral fusion inhibitors?

Current Opinion in Virology, 2012
Entry of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by attachment of the envelope glycoproteins, gp120 and gp41, to the CD4 receptor and a chemokine receptor (CCR5 or CXCR4) and subsequent fusion of viral and cellular membranes. Several steps of the entry process can be targeted by drugs.
Berkhout, Ben, Eggink, Dirk, Sanders, Rogier W.   +2 more
openaire   +2 more sources

Enfuvirtide: the first HIV fusion inhibitor

Expert Opinion on Pharmacotherapy, 2005
Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity.
openaire   +2 more sources